ZYME:NASDAQ
Zymeworks Inc
$24.04
arrow_downward
-4.22%(-1.06) 1D
$23.50
arrow_downward
-2.25% (-0.54)bedtimeAfter hours
Closed: Jun 5, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ZYME...
Open
$25.04
High
$25.12
Low
$24.02
Mkt. cap
1.76B
Avg. vol.
694.99K
Volume
464.86K
52-wk high
$29.75
52-wk low
$11.51
EPS
-$1.37
Beta
1.15
Shares outstanding
73.02M
No. of employees
243
Open
$25.04
High
$25.12
Low
$24.02
Mkt. cap
1.76B
Avg. vol.
694.99K
Volume
464.86K
52-wk high
$29.75
52-wk low
$11.51
EPS
-$1.37
Beta
1.15
Shares outstanding
73.02M
No. of employees
243
Analyst outlook
Analyst Ratings
Based on 9 analysts giving stock ratings to ZYME in the past 3 months
Strong Buy
Buy
9
Hold
0
Sell
0
12 month forecast
Based on 9 Wall Street analysts offering 12 month price targets for ZYME in the last 3 months.
Highest
Current $24.04
$48.00 (+99.67%)
Average
$39.88 (+65.89%)
Lowest
$34.00 (+41.43%)
News stories
From sources across the web
Simply Wall Street
·
17 hours ago
A Look At Zymeworks (ZYME) Valuation After Recent Clinical And Regulatory Milestones
Profile
Zymeworks Inc. is a publicly held biotechnology company based in Vancouver,
British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital that year. In May 2017, Zymeworks held an IPO on the Toronto Stock Exchange, raising $59 million. This was the largest Canadian biotech IPO in more than a decade. By alphabetical order, Zymeworks is the last company on the Toronto Stock Exchange.
In May 2019, Zymeworks announced that GSK has expanded its 2016 licensing and collaboration agreement for the research, development and commercialization of bispecific antibodies across multiple disease areas. The extended agreement has meant that GSK can have access to Zymeworks' heavy-light chain pairing technology, which enables the development of bispecific and multifunctional therapeutics. Wikipedia
About Zymeworks Inc
CEOKenneth Galbraith
Employees243
Founded2003
HeadquartersMiddletown, Delaware, United States
SectorBiotechnology
Websitezymeworks.com
AI content may include mistakes. Learn more